Vice President of Clinical and Translational Research,
Chair Department of Periodontology
email:
Case Western Reserve University, D.D.S., 1973
State University of New York at Buffalo, M.S., 1979, Oral Sciences
State University of New York at Buffalo, Certificate of Advanced Graduate Studies in Periodontology, 1980
State University of New York at Buffalo, Ph.D., 1982, Oral Biology
The Van Dyke laboratory focuses on basic research, clinical research and bridging the gap between the two through translational research. The long range goals of Dr. Van Dyke's basic science investigations is to gain further knowledge of the structural and functional relationship of the inflammatory process by defining the complex interactions between phagocytic cells and their environment, particularly microorganisms, including pathways of regulation of inflammation and resolution of inflammation as they influence pathogenesis of inflammatory disease and tissue regeneration.
Novel Mediators that Actively Resolve Inflammation and Enhance Bone and Tissue Regeneration
Dr. Van Dyke together with Dr. Serhan, a BWH scientist who identified novel components in the resolution of inflammation, has been working to use novel lipid mediators for the control of local inflammation. The potential of resolution molecules for the prevention and treatment of periodontal and other inflammatory diseases is being actively explored. Moreover, these same molecules, or longer acting analogs, are being evaluated to accelerate tissue regeneration and reconstruction of diseased and injured oral and craniofacial tissues. These new families of local mediators, termed lipoxins, resolvins and protectins, actively resolve acute inflammation in a programmed fashion that enables a return to tissue homeostasis.
Recent studies from Dr. Van Dyke’s laboratory have shown that in periodontitis and inflammation-induced bone destruction, these specialized lipid mediators reduce inflammation, protect from bone loss and strikingly, stimulate tissue regeneration. The role of these mediators in enhanced wound healing is now being studied using various in vivo and in vitro models including fibroblast healing in vitro, bone regeneration in rabbit periodontitis, and the formation of new cementum, periodontal ligament and new bone in minipigs.
Results from these studies are advancing our appreciation of mechanisms in natural resolution of inflammation. In addition, the therapeutic potential of resolvins in tissue regeneration and novel bioengineering-based strategies targeted for oral and craniofacial tissue regeneration is being determined.
Translational Research
The translational research program has the goal of developing basic knowledge and technologies for human use in biomedical sciences. Taking basic science discoveries to the clinic requires transfer of molecular and cellular discoveries to the tissue, organ and ultimately the whole organism level. The translational process is completed at the applied science level in human clinical trials. Current work by the Van Dyke laboratory is focused on the elucidation of factors inherent in the pathogenesis of periodontal diseases. By using basic research tools to gain an understanding of disease, the knowledge can be used in animal proof-of-principal trials before moving into human clinical application.
Clinical Research
In the Center for Clinical and Translational Research at Forsyth, the clinical research team performs studies that represent the last step in the process of development of new treatments. Clinical trials following FDA guidelines are performed at all levels, from early phase 1 trials to large, multicenter definitive clinical trials, with the goal of improving outcomes and the long-term health of patients.
Selected Publications
Stashenko P, Van Dyke T, Tully P, Kent R, Sonis S, Tanner AC. 2011. Inflammation and genetic risk indicators for early periodontitis in adults. J. Periodontol. (In press)
Herrera BS, Martins-Porto R, Campi P, Holzhausen M, Teixeira SA, Mendes GD, Costa SK, Gyurko R, Van Dyke TE, Spolkdόrio LC, Muscarά MN. 2011. Local and cardiorenal effects of periodontitis in nitric oxide-deficient hypertensive rats. Arch. Oral Biol. (In press)
Jagannathan M, Hasturk H, Liang Y, Shin H, Hetzel JT,Kantarci A, Rubin D, McDonnell ME, Van Dyke TE, Ganley-Leal LM, Nikolajczyk BS. 2010. TLR cross-talk specifically regulates cytokine production by B cells from chronic inflammatory disease patients. J. Immunol. 183(11):7461-7470.
Ohira T, Arita M, Omori K, Recchiuti A, Van Dyke TE, Serhan, CN. 2010. Resolvin E1 receptor activation signals phosphorylation and phagocytosis. J. Biol. Chem.285(5):3451-361.
Ayilavarapu S, Kantarci A, Fredman G, Turkoglu O, Omori K, Liu H, Iwata T, Yagi M, Hasturk H, Van DykeTE. 2010. Diabetes-induced oxidative stress is mediated by iPLA2 in PMNs. J Immunol. 184(3):1507-1515.
Janket S, Meurman JH, Baird AE, Qvarnstrom M, Nuutinen P, Ackerson LK, Hong J, Muthukrishnan P, Van Dyke TE.2010. Salivary immunoglobulins and prevent coronary artery disease. J. Dent. Res.89(4):389-394.
Genco RJ, Van Dyke TE. 2010. Prevention: Reducing the risk of CVD in patients with periodontitis. Nat. Rev. Cardiol. 7(9):479-480.
Zawawi KH, Kantarci A, Schulze-Späte U, Fujita T, Batista Jr EL, Amar S, Van Dyke TE. 2010. Moesin-induced signaling in response to lipopolysaccharide in macrophages. J. Periodontal Res. 45(5):589-601.
Qvarnstrom M, Janket SJ, Jones JA, Jethwani K, Nuutinen P, Garcia RI, Baird AE, Van Dyke TE, Meurman JH. 2010. Association of salivary lysozyme and C-reactive protein with metabolic syndrome. J. Clin. Periodontol. 37(9):805-811.
Fredman G, Van Dyke TE,Serhan CN. 2010. Resolvin E1 regulates adenosine diphosphate activation of human platelets. Arterioscler. Thromb. Vasc. Biol. 30(10):2005-2013.
Dornelles FN, Santos DS, Van Dyke TE, Calixto JB, Batista EL Jr, Campos MM. 2009. In vivo up-regulation of kinin B1 receptors after treatment with Porphyromonas gingivalis lipopolysaccharide in rat paw. J. Pharmacol. Exp. Ther. 330(3):756-763.
Iwata T, Kantarci A, Yagi M, Jackson T, Hasturk H, Kurihara H, Van Dyke TE. 2009. Ceruloplasmin induces polymorphonuclear leukocyte priming in localized aggressive periodontitis. J. Periodontol. 80(8):1300-1306.
Offenbacher S, Beck JD, Moss K, Mendoza L, Paquette DW, Barrow DA, Couper DJ, Stewart DD, Falkner KL, Graham SP, Grossi S, Gunsolley JC, Madden T, Maupome G, Trevisan M, Van Dyke TE, Genco RJ. 2009. Results from the Periodontitis and Vascular Events (PAVE) Study: A pilot multicentered, randomized, controlled trial to study effects of periodontal therapy in a secondary prevention model of cardiovascular disease.J. Periodontol. 80(2):190-201. PMCID: PMC2778200
Santana RB, de Mattos CM, Van Dyke T. 2009. Efficacy of combined regenerative treatments in human mandibular class II furcation defects. J. Periodontol. 80(11):1756-1764.
Shin H, Zhang Y, Jagannathan M, Hasturk H, Kantarci A, Liu H, Van Dyke TE, Ganley-Leal LM, Nikolajczyk BS. 2009. B cells from periodontal disease patients express surface toll-like receptor 4. J. Leukoc. Biol. 85(4):648-655.
Van Dyke TE. 2009. Resolution of inflammation-unraveling mechanistic links between periodontitis and cardiovascular disease. J. Dent.37(8):S582-S583.
Van Dyke TE. 2009. The etiology and pathogenesis of periodontitis revisited. Guest Editorial. J. Appl. Oral Sci. 17(1):pii: S1678-77572009000100001.
Yagi M, Kantarci A, Iwata T, Omori K, Ayilavarapu S, Ito K, Hasturk H, Van Dyke TE. 2009. PDK1 regulates chemotaxis in human neutrophils. J. Dent. Res. 88(12):1119-1124.
Herrera BS, Ohira T, Gao L, Omori K, Yang R, Zhu M, Muscara MN, Serhan CN, Van Dyke TE, Gyurko R. 2008. An endogenous regulator of inflammation, resolvin E1, modulates osteoclast differentiation and bone resorption. Br. J. Pharmacol. 155(8):1214-1223.
Serhan CN, Chiang N, Van Dyke TE. 2008. Resolving inflammation: Dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 8(5):349-361.
Omori K, Ohira T, Uchida Y, Ayilavarapu S, Batista EL Jr, Yagi M, Iwata T, Liu H, Hasturk H, Kantarci A, Van Dyke TE. 2008. Priming of neutrophil oxidative burst in diabetes requires preassembly of the NADPH oxi-dase. J Leukoc Biol. 84(1):292-301.
Hasturk H, Kantarci A, Goguet-Surmenian E, Blackwood A, Andry C, Serhan CN, Van Dyke TE. 2007. Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. J. Immunol. 179(10):7021-7029.
Ariel A, Fredman G, Sun Y, Kantarci A, Van Dyke TE, Luster AD, Serhan CN. 2006. Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression. Nat Immunol. 7(11):1209-1216.
Gronert K, Kantarci A, Levy B, Odparlik S, Hasturk H, Badwey, JA, Colgan SP, Van Dyke TE, Serhan CN. 2004. A molecular defect in intercellular lipid signaling in human neutrophils in localized aggressive perio-dontal tissue damage. J. Immunol. 72(3):1856-1861.
Gyurko R, Siqueira CC, Caldon N, Gao L, Kantarci A,Van Dyke TE. 2006. Chronic hyperglycemia predisposes to exaggerated inflammatory response and leukocyte dysfunction in Akita mice. J. Immunol. 177 (10):7250-7256.
Hasturk H, Kantarci A, Ohira T, Arita M, Ebrahimi N, Chiang N, Petasis NA, Levy BD, Serhan CN, Van Dyke TE.2006. RvE1 protects from local inflammation and osteoclast- mediated bone destruction in perio-dontitis. FASEB J. 20(2):401-403.
Gronert K, Kantarci A, Levy B, Odparlik S, Hasturk H, Badwey, JA, Colgan SP, Van Dyke TE, Serhan CN. 2004. A molecular defect in intercellular lipid signaling in human neutrophils in localized aggressive perio-dontal tissue damage. J. Immunol. 72(3):1856-1861.
